DE69232629T2 - Verwendung von transglutaminasehemmer zur behandlung des narbegewebes - Google Patents

Verwendung von transglutaminasehemmer zur behandlung des narbegewebes

Info

Publication number
DE69232629T2
DE69232629T2 DE69232629T DE69232629T DE69232629T2 DE 69232629 T2 DE69232629 T2 DE 69232629T2 DE 69232629 T DE69232629 T DE 69232629T DE 69232629 T DE69232629 T DE 69232629T DE 69232629 T2 DE69232629 T2 DE 69232629T2
Authority
DE
Germany
Prior art keywords
pct
scar tissue
treatment
sec
amine compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232629T
Other languages
English (en)
Other versions
DE69232629D1 (de
Inventor
Kenneth N Dolynchuk
John Michael Bowness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
University of Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manitoba filed Critical University of Manitoba
Application granted granted Critical
Publication of DE69232629D1 publication Critical patent/DE69232629D1/de
Publication of DE69232629T2 publication Critical patent/DE69232629T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69232629T 1992-03-23 1992-03-23 Verwendung von transglutaminasehemmer zur behandlung des narbegewebes Expired - Lifetime DE69232629T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA1992/000123 WO1993018760A1 (en) 1992-03-23 1992-03-23 Use of transglutaminase inhibitor for the treatment of scar tissue

Publications (2)

Publication Number Publication Date
DE69232629D1 DE69232629D1 (de) 2002-07-11
DE69232629T2 true DE69232629T2 (de) 2003-01-30

Family

ID=4172922

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232629T Expired - Lifetime DE69232629T2 (de) 1992-03-23 1992-03-23 Verwendung von transglutaminasehemmer zur behandlung des narbegewebes

Country Status (10)

Country Link
US (1) US5885982A (de)
EP (1) EP0632723B1 (de)
AT (1) ATE218330T1 (de)
AU (1) AU674828B2 (de)
BR (1) BR9207109A (de)
CA (1) CA2132416C (de)
DE (1) DE69232629T2 (de)
DK (1) DK0632723T3 (de)
ES (1) ES2177527T3 (de)
WO (1) WO1993018760A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6620596A (en) * 1996-07-25 1998-02-20 Victoria University Of Manchester, The Use of transglutaminase modulators to promote wound healing
US6060471A (en) * 1998-01-21 2000-05-09 Styczynski; Peter Reduction of hair growth
JP3012923B2 (ja) * 1998-01-26 2000-02-28 新潟大学長 Ｃａｇリピート病の治療薬
US20040067212A1 (en) 1998-03-11 2004-04-08 Kabushiki Kaisha Soken Skin conditioner
AU2006203098B2 (en) * 1998-03-11 2009-10-08 Kabushiki Kaisha Soken Skin conditioner
CA2323451C (en) * 1998-03-11 2013-01-08 Kabushiki Kaisha Soken Skin conditioner
IL138732A0 (en) * 1998-04-03 2001-10-31 Univ Manitoba The use of polyamines in the treatment of dermatological symptoms
CN1406123B (zh) * 1999-09-07 2010-04-21 株式会社创研 皮肤健全化剂
EP1645248B8 (de) * 2000-02-04 2010-06-16 Warsaw Orthopedic, Inc. Ausdehnbares interspinales Fusionsimplantat mit schwenkbarem Blocker
US6500205B1 (en) * 2000-04-19 2002-12-31 Gary K. Michelson Expandable threaded arcuate interbody spinal fusion implant with cylindrical configuration during insertion
US6814756B1 (en) * 2000-02-04 2004-11-09 Gary K. Michelson Expandable threaded arcuate interbody spinal fusion implant with lordotic configuration during insertion
US6716247B2 (en) 2000-02-04 2004-04-06 Gary K. Michelson Expandable push-in interbody spinal fusion implant
US6709458B2 (en) 2000-02-04 2004-03-23 Gary Karlin Michelson Expandable push-in arcuate interbody spinal fusion implant with tapered configuration during insertion
US6808537B2 (en) * 2000-07-07 2004-10-26 Gary Karlin Michelson Expandable implant with interlocking walls
US7118579B2 (en) 2001-02-04 2006-10-10 Sdgi Holdings, Inc. Instrumentation for inserting an expandable interbody spinal fusion implant
WO2003013245A1 (en) 2001-08-07 2003-02-20 Wisconsin Alumni Research Foundation Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
WO2007069817A1 (en) * 2005-12-16 2007-06-21 National Cancer Center Peptides for inhibiting transglutaminase
CA2706630A1 (en) * 2007-11-27 2009-06-04 Kenneth Nicholis Dolynchuk Use of transglutaminase inhibitor in skin treatment
US20100316764A1 (en) * 2009-06-10 2010-12-16 Engrain, LLC Flour supplement compositions and methods for preparing wheat flour
US20190298688A1 (en) * 2016-11-21 2019-10-03 Vivier Canada Inc. Putrescine slow-release topical formulations
US20190314299A1 (en) * 2017-01-06 2019-10-17 Vivier Canada Inc. Putrescine topical barrier formulation
WO2019232644A1 (en) * 2018-06-08 2019-12-12 Vivier Canada Inc. Sterile topical saline putrescine formulation and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1588110A (en) * 1978-05-31 1981-04-15 Geistlich Soehne Ag Pharmaceutical compositions for the treatment of scars
US4618490A (en) * 1980-06-06 1986-10-21 Marco Peter T De Method of treatment of animal and human tissues damaged by burns and frank visible gangrene
US4444787A (en) * 1981-07-06 1984-04-24 Board Of Regents, University Of Texas Ophthalmic topical use of collagen cross-linking inhibitors
US4428939A (en) * 1981-10-16 1984-01-31 Prockop Darwin J Collagen inhibiting compositions and processes for manufacturing and using same
US4507321A (en) * 1982-02-17 1985-03-26 The Research Foundation Of State University Of New York Epithelial cell growth regulating composition containing polyamines and a method of using same
US4485088A (en) * 1982-03-26 1984-11-27 Bio-Products, Inc. Method of treatment of fibrotic lesions by topical administration of lathyrogenic drugs
US4929630A (en) * 1986-03-14 1990-05-29 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
US4694021A (en) * 1986-05-05 1987-09-15 Schweiger Raymond H Method for topical treatment of scar tissue
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
US4970297A (en) * 1987-03-13 1990-11-13 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
US4968713A (en) * 1989-07-31 1990-11-06 Merck & Co., Inc. Certain imidazole compounds as transglutaminase inhibitors
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers
US4997854A (en) * 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5124358A (en) * 1990-01-16 1992-06-23 The Board Of Reagents The University Of Texas System Effect of transglutaminase inhibition on microfilariae development and macrofilariae viability
US5324508A (en) * 1990-06-11 1994-06-28 The Curators Of The University Of Missouri Method for decreasing the formation of scar tissue using a purified mammalian monokine product
US5120322A (en) * 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma

Also Published As

Publication number Publication date
AU674828B2 (en) 1997-01-16
WO1993018760A1 (en) 1993-09-30
CA2132416C (en) 2001-03-06
ATE218330T1 (de) 2002-06-15
EP0632723B1 (de) 2002-06-05
ES2177527T3 (es) 2002-12-16
US5885982A (en) 1999-03-23
EP0632723A1 (de) 1995-01-11
CA2132416A1 (en) 1993-09-30
DE69232629D1 (de) 2002-07-11
AU1544892A (en) 1993-10-21
DK0632723T3 (da) 2002-09-09
BR9207109A (pt) 1995-12-12

Similar Documents

Publication Publication Date Title
DE69232629D1 (de) Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
DE69924641D1 (de) Behandlung von asthma anhand von mek-inhibitoren
DE69204162D1 (de) Zusammensetzung auf der basis von silikon und latex zur behandlung von keratinösen substanzen.
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE69616375T2 (de) Nicht-allosterische GABA A Agonisten zur Behandlung von Schlafstörungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69317578T2 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE69719408D1 (de) Verwendung von Strontiumsälze zur Behandlung von Arthrose
DE69727695D1 (de) Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
EP0646007A4 (de)
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
DE60315238D1 (de) Verwendung eines Assoziates aus synergistischen Kalziumkanalblocker-Agentien zur Vermeidung oder Behandlung von Falten und feinen Linien
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
ATE226058T1 (de) Verwendung von lysin zur behandlung des haarausfalls
DE69613041D1 (de) Verwendung von Erdalkalimetalsalzen in Mitteln zur Behandlung van Augen- oder Augenlidschmerzen oder Dysesthesien
DE69330465T2 (de) Verfahren zur behandlung von chronischer prostatitis mit 17-beta-n-tertbutylcarbamoyl-4-aza-5 alpha-androst-1-en-3-one
ES2163528T3 (es) Una solucion acuosa para infusion, estable al almacenamiento, que contiene un inhibidor de trombina.
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition